Zentiva Completes Voluntary Public Purchase Offer for APONTIS PHARMA AG

AptarGroup Completes Acquisition of Majority Stake in Voluntis (Theraxium Digital Therapeutics)

September 2, 2021

Healthcare Services

AptarGroup, Inc. entered into exclusive negotiations and subsequently completed the acquisition of a majority stake (approximately 64.6%) in Voluntis, a digital therapeutics company. The transaction was followed by a mandatory cash tender offer to acquire Voluntis’ remaining shares at €8.70 per share, with a potential squeeze-out if regulatory conditions are met.

GTCR Acquires Zentiva from Advent

September 11, 2025

Pharmaceuticals

Advent and GTCR announced the sale of Zentiva, a leading European generics pharmaceutical company, with Advent selling Zentiva to GTCR. The transaction is subject to regulatory approvals and is expected to close in early 2026.

Qvantel Acquires Optiva Inc.

December 31, 2025

Software

Qvantel Oy completed its acquisition of Optiva Inc. via a statutory plan of arrangement, acquiring all issued and outstanding common shares of Optiva. The transaction paid Optiva shareholders C$0.25 per common share, cancelled Optiva's US$108.6 million PIK notes with consideration to noteholders (including purchaser shares, purchaser-issued senior secured notes and warrants), and will result in Optiva being dissolved and delisted from the Toronto Stock Exchange. The combined company expands Qvantel's telecom monetization and digital operations portfolio and supports more than 70 operators with a global workforce exceeding 1,000 professionals.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva agreed to acquire the remaining shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis equity at about $113 million on a fully diluted basis. Innoviva completed the acquisition in July 2022, making Entasis a wholly owned subsidiary.

Roche Buys Telavant Holdings (Roivant/Pfizer) for $7.1B+

October 26, 2023

Healthcare Services

Roche entered into a definitive agreement to acquire Telavant Holdings, a company jointly owned by Roivant and Pfizer, for an upfront purchase price of $7.1 billion plus a near-term $150 million milestone payment. The deal gives Roche full rights to further develop, manufacture, and commercialize Telavant’s TL1A-directed antibody RVT-3101 in the US and Japan, with Pfizer retaining commercialization rights outside those territories.

Azurity Pharmaceuticals Acquires Covis Pharma

March 14, 2025

Pharmaceuticals

Azurity Pharmaceuticals has completed its acquisition of Covis Group S.à r.l. (Covis Pharma) from existing investors, making Covis a wholly owned subsidiary of Azurity. The deal expands Azurity's therapeutic portfolio across multiple complex dosage forms and broadens its global footprint, with the combined company serving 50+ countries and employing more than 800 colleagues.